Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer
March 28, 2022 09:25 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th
March 22, 2022 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling...
Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update
March 21, 2022 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling...
Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol
March 02, 2022 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update
January 12, 2022 08:30 ET
|
Artelo Biosciences
Complete Enrollment of Phase 1 CAReS Trial Anticipated by End of First Quarter of Calendar Year 2022 $26.4 Million in Cash and Marketable Securities as of November 30, 2021 SOLANA BEACH, Calif.,...
Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
January 11, 2022 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the United Kingdom’s Home Office has classified the Company’s lead clinical...
Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 10, 2022 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling...
Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
November 29, 2021 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling...
Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling...
Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
August 04, 2021 08:30 ET
|
Artelo Biosciences
Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD Study further validates Artelo’s...